Share Facebook
Crohn's Disease Forum » Books, Multimedia, Research & News » Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease


06-07-2014, 08:02 AM   #1
DustyKat
Super Moderator
 
DustyKat's Avatar
 
Join Date: May 2010
Location: New South Wales, Australia
Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease

Abstract

The thiopurine drugs, 6-mercaptopurine (6-MP) and azathioprine, are efficacious in the arsenal of inflammatory bowel disease (IBD) therapy.

Previous reports indicate that 6-thioguanine nucleotide (6-TGN) levels correlate with therapeutic efficacy, whereas high 6-methylmercaptopurine (6-MMP) levels are associated with hepatotoxicity and myelotoxicity.

Due to their complex metabolism, there is wide individual variation in patient response therein, both in achieving therapeutic drug levels as well as in developing adverse reactions. Several strategies to optimize 6-TGN while minimizing 6-MMP levels have been adopted to administer the thiopurine class of drugs to patients who otherwise would not tolerate these drugs due to side-effects.

In this report, we will review different approaches to administer the thiopurine medications, including the administration of 6-mercaptopurine in those unsuccessfully treated with azathioprine; co-administration of thiopurine with allopurinol; co-administration of thiopurine with anti-tumor necrosis factor α; 6-TGN administration; desensitization trials; and split dosing of 6-MP.
Full Article:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3208360/
__________________
Mum of 2 kids with Crohn's.
Reply

Crohn's Disease Forum » Books, Multimedia, Research & News » Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease
Thread Tools


All times are GMT -5. The time now is 05:49 AM.
Copyright 2006-2017 Crohnsforum.com